Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study

Ruth Brauer; Krishnan Bhaskaran; Nishi Chaturvedi; David T. Dexter; Liam Smeeth; Ian Douglas

doi:10.1371/journal.pmed.1001854

Loading metrics

Open Access

Peer-reviewed

Research Article

Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study

Ruth Brauer ,

* E-mail: Ruth.brauer@lshtm.ac.uk

Affiliation Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom
⨯
Krishnan Bhaskaran,

Affiliation Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom
⨯
Nishi Chaturvedi,

Affiliation Institute of Cardiovascular Sciences, University College London, London, United Kingdom
⨯
David T. Dexter,

Affiliation Centre for Neuroinflammation & Neurodegeneration, Division of Brain Sciences, Faculty of Medicine, Imperial College, London, United Kingdom
⨯
Liam Smeeth,

Affiliation Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom
⨯
Ian Douglas

Affiliation Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom
⨯

Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study

Ruth Brauer,
Krishnan Bhaskaran,
Nishi Chaturvedi,
David T. Dexter,
Liam Smeeth,
Ian Douglas

Published: July 21, 2015
https://doi.org/10.1371/journal.pmed.1001854

Reader Comments

Post a new comment on this article

Exenatide also exhibits activity against Parkinson's disease

Posted by DavidLouisKeller on 22 Jul 2015 at 20:22 GMT

The type-2 diabetes drug exenatide also has exhibited symptomatic benefits in Parkinson's disease, in a prospective randomized interventional trial [1], with persistent motor and cognitive benefits which suggest possible disease modification. Exenatide is not a thiazolidinedione ("glitazone"), and its concomitant use should be accounted for in the glitazone study, to avoid skewed results.

1: Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P,
Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T. Motor and cognitive
advantages persist 12 months after exenatide exposure in Parkinson's disease. J
Parkinsons Dis. 2014;4(3):337-44. doi: 10.3233/JPD-140364. PubMed PMID: 24662192.

No competing interests declared.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Diabetes mellitus
Is the Subject Area "Diabetes mellitus" applicable to this article?

Thanks for your feedback.
Parkinson disease
Is the Subject Area "Parkinson disease" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Epidemiology
Is the Subject Area "Epidemiology" applicable to this article?

Thanks for your feedback.
Primary care
Is the Subject Area "Primary care" applicable to this article?

Thanks for your feedback.
Cohort studies
Is the Subject Area "Cohort studies" applicable to this article?

Thanks for your feedback.
Drug research and development
Is the Subject Area "Drug research and development" applicable to this article?

Thanks for your feedback.
Neuroprotectives
Is the Subject Area "Neuroprotectives" applicable to this article?

Thanks for your feedback.

Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study

Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study

Reader Comments

Post Your Discussion Comment

Why should this posting be reviewed?

Thank You!

Exenatide also exhibits activity against Parkinson's disease

Posted by DavidLouisKeller on 22 Jul 2015 at 20:22 GMT